A new study published in The Lancet indicates that zoliflodacin, a single-dose antibiotic, has proven to be as effective as standard treatment in the treatment of uncomplicated urogenital gonorrhea. This antibiotic represents a potential solution in a field where options are limited. The Food and Drug Administration (FDA) has set December 15 as the date to decide on the approval of zoliflodacin. The decision will significantly impact the fight against Neisseria gonorrhoeae, the pathogen that causes the infection. The drug was developed by Innoviva Specialty Therapeutics and the Global Antibiotic Research and Development Partnership (GARDP), highlighting the importance of cooperation between the public and private sectors to address challenges in the health field. “In our setting, where ceftriaxone remains effective, I see zoliflodacin as a second-line option, especially in situations where standard treatment is ineffective,” Dr. Oriol Mitja, head of the infectious diseases section at Germans Trias i Pujol Hospital (Barcelona, ??Spain) and president-elect of the International Society for Sexually Transmitted Disease Research, told Science Media Centre. Comparison with other treatments: Zoliflodacin shows comparable efficacy to standard treatment for uncomplicated urogenital gonorrhea, with rates Microbiological cure rate of approximately 90-91% compared to 96% for the ceftriaxone plus azithromycin combination.

Its unique mechanism inhibits bacterial type II topoisomerase, active against ceftriaxone- and azithromycin-resistant strains without cross-resistance. This phase 3 study confirms statistical non-inferiority in urogenital sites.

Its advantage lies in single oral administration (3 g), avoiding painful injections like those required for ceftriaxone.

It has a tolerable profile, with slightly more frequent headaches (9.9% vs. 4.5%), but less nausea and diarrhea than the standard (2.4% vs. 7%).1%). Neutropenia was comparable between groups. It is generally considered well tolerated.

Potential beneficiaries

Those who would benefit most from this advance would be patients with uncomplicated gonorrhea, including urogenital and rectal forms, especially those with strains resistant to ceftriaxone and azithromycin, where it has shown cure rates exceeding 90%.

Its administration in a single oral dose facilitates global access, benefiting populations in areas with limited medical resources or a high burden of bacterial STIs. This supports the World Health Organization's (WHO) goals to reduce the incidence of gonorrhea by 90% by 2030.

Blujeba License for Gonorrhea

In a parallel development, the U.S. Food and Drug Administration (FDA) also approved an extension of the license for the antibiotic Blujeba (gepotidacin) for use in the treatment of urogenital gonorrhea.

This step reflects an increase in the options available to treat this common infection.

You may also be interested in: